The CAR-T therapies market is characterized by a healthy pipeline of promising therapies, and is projected to be worth around USD 14 Billion in 2030, claims Roots Analysis

Published: April 2021

Given the success of approved CAR-T cell therapies, such as KYMRIAH®, YESCARTA®, TECARTUS® and BREYANZI®, this upcoming class of biologics are anticipated to carve out a significant share of the multi-billion dollar cancer immunotherapy market

Roots Analysis has announced the addition of CAR T Cell Therapy Market report to its list of offerings. 

Given their ability to selectively direct a cell mediated immune response against cancer cells and, thereby, offer prolonged periods of disease remission, several CAR-T cell therapies provide a promising therapeutic strategy for advanced stage cancers and are expected to achieve blockbuster status. With four approved products and many candidate therapies under evaluation for the treatment of multiple disease indications, the CAR-T cell therapy market is characterized by a healthy and growing pipeline. Further, with lucrative financial support and notable increase in partnerships, the CAR-T-cell therapies market is abuzz with activity.

To order this 795+ page report, which features 165+ figures and 270+ tables, please visit

Key Market Insights 

Over 755 CAR-T cell therapies are currently approved / under development 
Close to 40% of the aforementioned candidates are in preclinical and discovery stages, while more than 25% are being evaluated in clinical stages (phase I/II and above). Examples of late-stage clinical candidates include bb2121, CD123/CLL1 CAR-T CD19 CAR-T and LCAR-B38M CAR-T / JNJ-68284528. 

Currently, the focus is on developing product candidates to treat various types of cancers 
Over 95% of the products in the development pipeline are being evaluated for the treatment of hematological malignancies, including (in decreasing order of number of pipeline products) acute lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, and acute myeloid leukemia. Only 2% of current pipeline candidates are being developed for the treatment of non-oncological indications.

Extensive efforts are underway to improve CAR constructs
Majority of the product candidates in the clinical pipeline, including the four approved drug products, are based on second generation CARs. Further, a number of novel therapies armed with fourth generation CAR constructs, CAR-based products containing humanized scFv and bispecific CARs (CD19+CD20 or CD19+CD22 or CD19+CD30) are being evaluated worldwide.

China is leading the product development efforts related to CAR-T cell therapies, in terms of number of active trials and supporting hospitals
In the last 10 years, over half of the 410 clinical trials evaluating various types of CAR-T cell therapies, were registered in China. In addition, owning to a favorable clinical research environment, China is presently considered to be among the leading regions in the CAR-T cell therapy space, with close to 40 industry players and more than 100 non-industry players, including hospitals and universities, contributing to this field.

Partnership activity within this domain has grown at a CAGR of 26%, between 2011 and 2020
More than 220 agreements were inked related to CAR-T cell therapies, with the maximum activity being reported in 2018. Majority of partnership deals signed within this domain were R&D agreements (21%), technology licensing (20%) and product development and commercialization agreements (11%).
Over USD 13 billion has been invested by both private and public investors, across more than 205 instances 
It is important to mention that, between 2013 and 2020, majority of the funding was acquired through venture capital rounds (37%), other equity financing elements (24%), grants (12%) and secondary offerings (12%).

The market is anticipated to grow at a CAGR of over 28%, during the period 2021-2030
Growth in this domain is anticipated to be primarily driven by encouraging clinical trial results and the recent success of the four approved CAR-T cell therapies. North America (primarily the US) and Europe are expected to capture over 75% of the market share by 2030, in terms of the sales-based revenues.

You Can Download Free Sample PDF Copy of This Report At:

Key Questions Answered

  • Who are the leading industry and non-industry players in this market?
  • What are the prevalent R&D trends in CAR-T cell therapies domain?
  • What are the key therapeutic areas for which CAR-T cell therapies are being / have been developed?
  • What are the challenges faced by stakeholders in this industry?
  • Which are the key geographies where extensive research on CAR-T cell therapies is being conducted?
  • Who are the key investors in this domain? 
  • Who are the key opinion leaders / experts that can help in driving product development efforts in this field?
  • What kind of partnership models are commonly adopted by industry stakeholders? 
  • What kind of contract manufacturing support is available for CAR-T cell therapies?
  • What kind of promotional strategies are likely to be adopted for CAR-T cell therapies that are approved / commercialized in future?
  • What are the factors that are likely to influence the evolution of this upcoming market?
  • How is the current and future market opportunity likely to be distributed across key market segments? 

The USD 14 billion (by 2030) financial opportunity within the CAR-T cell therapy market has been analyzed across the following segments: 

  • Disease indication
    • Non-Hodgkin lymphoma
    • Multiple myeloma
    • Chronic lymphocytic leukemia
    • Acute lymphoblastic leukemia
    • Follicular lymphoma
    • Mantle cell lymphoma
    • Hepatocellular carcinoma
    • Colorectal cancer
  • Target antigens
    • CD19
    • BCMA
    • CD19, CD22
    • GPC3
    • EGFR
  • Key Geographical Regions 
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East and North Africa
    • Rest of the World 

The report features inputs from eminent industry stakeholders, according to whom CAR-T cell therapies are soon likely to witness increased adoption given their broad scope of applications in various advanced stage oncological disorders. The report includes detailed transcripts of discussions held with the following experts:

  • Former Chief Executive Officer, Small Company, The Netherlands
  • Chief Executive Officer, Founder and Chairman , Mid-sized Company, China
  • Former Chief Operating Officer , Small Company, France
  • Former Vice President, Large Company, US
  • Former Vice President Immuno-Oncology, Small Company, Belgium
  • Director Business Development, Small Company, US
  • Former Competitive Intelligence Manager, Small Company, France
  • Professor, Key Opinion Leader, China
  • Assistant Professor, Key Opinion Leader, US

The research includes brief profiles, featuring an overview of the company, its financial information (if available), and a description of its product(s), highlighting type of therapy and current development status. Each company profile includes technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies. 

  • Autolus
  • bluebird bio
  • CARsgen Therapeutics
  • Celgene (A Bristol Myers Squibb Company)
  • Cellectis
  • Cellular Biomedicine Group
  • Innovative Cellular Therapeutics
  • Iovance Biotherapeutics
  • Kite Pharma (A Gilead Sciences Company)
  • Kuur Therapeutics
  • Noile-Immune Biotech
  • Novartis
  • Shanghai Genechem
  • Sinobioway Cell Therapy
  • Takara Bio
  • Ziopharm Oncology

For additional details, please email at

You may also be interested in the following titles: 

  1. Global T-Cell Therapies Market
  2. mRNA Therapeutics and Vaccines Market
  3. Gene Therapies Market (4th Edition): Industry Trends and Global Forecasts
  4. Oncolytic Virus Therapy Market: Pipeline Review, Developer Landscape and Competitive Insights

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091


  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry